Logo image of UBX

UNITY BIOTECHNOLOGY INC (UBX) Stock Fundamental Analysis

NASDAQ:UBX - Nasdaq - US91381U2006 - Common Stock - Currency: USD

0.798  -0.06 (-6.76%)

After market: 0.786 -0.01 (-1.5%)

Fundamental Rating

1

Overall UBX gets a fundamental rating of 1 out of 10. We evaluated UBX against 559 industry peers in the Biotechnology industry. UBX may be in some trouble as it scores bad on both profitability and health. UBX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

UBX had negative earnings in the past year.
UBX had a negative operating cash flow in the past year.
In the past 5 years UBX always reported negative net income.
In the past 5 years UBX always reported negative operating cash flow.
UBX Yearly Net Income VS EBIT VS OCF VS FCFUBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -90.63%, UBX is not doing good in the industry: 73.70% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -90.63%
ROE N/A
ROIC N/A
ROA(3y)-55.15%
ROA(5y)-54.83%
ROE(3y)-206.62%
ROE(5y)-167.01%
ROIC(3y)N/A
ROIC(5y)N/A
UBX Yearly ROA, ROE, ROICUBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for UBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UBX Yearly Profit, Operating, Gross MarginsUBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for UBX has been increased compared to 1 year ago.
Compared to 5 years ago, UBX has more shares outstanding
UBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UBX Yearly Shares OutstandingUBX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
UBX Yearly Total Debt VS Total AssetsUBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

UBX has an Altman-Z score of -26.27. This is a bad value and indicates that UBX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -26.27, UBX is not doing good in the industry: 88.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.27
ROIC/WACCN/A
WACCN/A
UBX Yearly LT Debt VS Equity VS FCFUBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

UBX has a Current Ratio of 1.95. This is a normal value and indicates that UBX is financially healthy and should not expect problems in meeting its short term obligations.
UBX has a Current ratio of 1.95. This is in the lower half of the industry: UBX underperforms 76.57% of its industry peers.
A Quick Ratio of 1.95 indicates that UBX should not have too much problems paying its short term obligations.
UBX has a worse Quick ratio (1.95) than 74.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.95
UBX Yearly Current Assets VS Current LiabilitesUBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

UBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.94%, which is quite impressive.
EPS 1Y (TTM)23.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, UBX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.84% on average per year.
UBX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -16.43% yearly.
EPS Next Y17.18%
EPS Next 2Y22.49%
EPS Next 3Y17.98%
EPS Next 5Y15.84%
Revenue Next Year-100%
Revenue Next 2Y-37.99%
Revenue Next 3Y9.42%
Revenue Next 5Y-16.43%

3.3 Evolution

UBX Yearly Revenue VS EstimatesUBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2022 2024 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M 40M 50M
UBX Yearly EPS VS EstimatesUBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

UBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year UBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UBX Price Earnings VS Forward Price EarningsUBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UBX Per share dataUBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

UBX's earnings are expected to grow with 17.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.49%
EPS Next 3Y17.98%

More info and screens

0

5. Dividend

5.1 Amount

UBX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNITY BIOTECHNOLOGY INC

NASDAQ:UBX (6/13/2025, 8:00:02 PM)

After market: 0.786 -0.01 (-1.5%)

0.798

-0.06 (-6.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-22 2025-04-22/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners17.19%
Inst Owner Change-4.49%
Ins Owners1.57%
Ins Owner Change7.63%
Market Cap13.73M
Analysts77.5
Price Target3.32 (316.04%)
Short Float %4.44%
Short Ratio3.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.38%
Min EPS beat(2)-22.33%
Max EPS beat(2)-6.44%
EPS beat(4)2
Avg EPS beat(4)3.37%
Min EPS beat(4)-22.33%
Max EPS beat(4)33.56%
EPS beat(8)6
Avg EPS beat(8)17.28%
EPS beat(12)10
Avg EPS beat(12)18.78%
EPS beat(16)12
Avg EPS beat(16)18.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-35%
PT rev (3m)-50%
EPS NQ rev (1m)4.26%
EPS NQ rev (3m)-104.54%
EPS NY rev (1m)2.59%
EPS NY rev (3m)9.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-1.28
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.63%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.15%
ROA(5y)-54.83%
ROE(3y)-206.62%
ROE(5y)-167.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.95
Quick Ratio 1.95
Altman-Z -26.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1.78%
Cap/Depr(5y)6.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.47%
EPS Next Y17.18%
EPS Next 2Y22.49%
EPS Next 3Y17.98%
EPS Next 5Y15.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-37.99%
Revenue Next 3Y9.42%
Revenue Next 5Y-16.43%
EBIT growth 1Y21.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.3%
EBIT Next 3Y-7.08%
EBIT Next 5YN/A
FCF growth 1Y54.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.8%
OCF growth 3YN/A
OCF growth 5YN/A